Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Taylor Cancer Research Center

Maumee, Ohio 43537, United StatesNot linked to an institution yet

24running trials
1closed trial

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions: Lung cancer11 trials
Pancreatic cancer7 trials
Colorectal cancer5 trials
Bladder cancer3 trials
Childhood cancers3 trials
Follicular lymphoma2 trials
Gastric and oesophageal cancer2 trials
Liver and biliary tract cancer2 trials
Melanoma2 trials
Metastatic breast cancer2 trials
Ovarian cancer2 trials
Acute myeloid leukaemia1 trial
and 8 more
Phase: Phase 1/28 trials
Phase 38 trials
Phase 13 trials
Phase 22 trials
Status: Recruiting18 trials
Active, not recruiting5 trials
Completed1 trial
Not yet recruiting1 trial
Lead sponsor: Revolution Medicines, Inc.4 trials
Tempus AI3 trials
Artios Pharma Ltd1 trial
Bayer1 trial
Carna Biosciences, Inc.1 trial
and 15 more

Running trials

Recruiting
A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
NCT07905001· Phase 1· Prelude Therapeutics Incorporated· Source
Not yet recruiting
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
NCT07910942· Phase 1· Kanvas Biosciences· Source
Contact: Stephanie Ambrose
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· Phase 3· Immuneering Corporation· Source
Contact: Stephanie Ambrose
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source
Contact: Stephanie Ambrose
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
NCT07154823· Tempus AI· Source
Contact: Jennifer Martinez
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232· Phase 3· Revolution Medicines, Inc.· Source
Contact: Stephanie Ambrose
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257· Phase 1/2· Tasca Therapeutics· Source
Contact: Stephanie Ambrose, RN, BSN, CCRC
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636· Phase 1/2· Pathos AI, Inc.· Source
Contact: Stephanie Ambrose
Recruiting
Pan-tumor MRD Study
NCT06605404· Paradigm Health· Source
Contact: Jennifer Martinez
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285· Phase 2· Puma Biotechnology, Inc.· Source
Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· Phase 3· Bayer· Source
Active, not recruiting
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702· Phase 1/2· Servier Bio-Innovation LLC· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363· Phase 1· Carna Biosciences, Inc.· Source
Contact: Nadine Nemunaitis
Recruiting
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797· Phase 2· Fore Biotherapeutics· Source
Contact: Jessica Rine
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Source
Contact: Jennifer Martinez
Recruiting
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198· Phase 1/2· Disc Medicine, Inc· Source
Contact: Nadine Nemunaitis
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985· Phase 1/2· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines, Inc.
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· Phase 1/2· Artios Pharma Ltd· Source
Contact: Sarah Cannon Development Innovations
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835· Phase 1/2· Genmab· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer7 recruiting
Colorectal cancer5 recruiting
Pancreatic cancer5 recruiting
Bladder cancer3 recruiting
Childhood cancers2 recruiting
Follicular lymphoma2 recruiting
Gastric and oesophageal cancer2 recruiting
Melanoma2 recruiting
Metastatic breast cancer2 recruiting
Ovarian cancer2 recruiting
Acute myeloid leukaemia1 recruiting
Chronic lymphocytic leukaemia1 recruiting
Endometrial cancer1 recruiting
Head and neck cancer1 recruiting
Liver and biliary tract cancer1 recruiting
Mantle cell lymphoma1 recruiting
Myelodysplastic syndromes1 recruiting
Myeloproliferative neoplasms1 recruiting
Prostate cancer1 recruiting
Thyroid cancer1 recruiting

Closed trials

Completed
Umbrella Study for Analysis of Data Related to Patients With Cancer
NCT06018753· Tempus AI· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error